It is well recognised that the metabolic syndrome, a constellation of risk factors including obesity, hypertension, insulin resistance and dyslipidaemia, is associated with an increased risk of cardiovascular complications and the development of Type 2 diabetes. Consequently, timely identification and management of all components of the metabolic syndrome is warranted. In particular, guidelines have emphasised the importance of targeting elevated blood pressure (BP) and dyslipidaemia as a method of reducing global cardiovascular risk.
Findings from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial show that the angiotensin receptor blocker, valsartan, reduces cardiovascular events and the development of Type 2 diabetes in high-risk individuals. This profile is being further explored in the ongoing Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
Given the potential advantages to patients and physicians of tackling more than one of the components of the metabolic syndrome, antihypertensive agents such as valsartan would appear to be an important addition to the management of vulnerable patients at high risk of cardiovascular events.
DeedwaniaPC. Metabolic syndrome and vascular disease. Is nature or nurture leading the new epidemic of cardiovascular disease?Circulation2004; 109: 2–4.
2.
HallJE, CrookED, JonesDW, WoffordMR, DubbertPM. Mechanisms of obesity-associated cardiovascular and renal disease.Am J Med Sci2002; 324: 127–37.
3.
DeedwaniaPC, VolkovaN. Current treatment options for the metabolic syndrome.Curr Treat Options Cardiovasc Med2005; 7: 61–74.
4.
LandsbergL. Insulin and hypertension: lessons from obesity.N Engl J Med1987; 317: 378–95.
5.
ReavenGM. Role of insulin resistance in human disease (syndrome X): an expanded definition.Annu Rev Med1993; 44: 121–31.
6.
GrundySM, BrewerHB, CleemanJI. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute/American Heart Conference on scientific issues related to definition.Arterioscler Thromb Vasc Biol2004; 24: e13–18.
7.
AlbertiKG, ZimmetPZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation.Diabet Med1998; 15: 539–53.
8.
Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).JAMA2001; 285: 2486–97.
9.
LakkaHM, LaaksonenDE, LakkaTA. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.JAMA2002; 288: 2709–16.
10.
NinomiyaJK, L'ItalienG, CriquiMH. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.Circulation2004; 109(1): 42–6.
11.
LaaksonenDE, LakkaHM, NiskanenLK. Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study.Am J Epidemiol2002; 156: 1070–7.
12.
HansonRL, ImperatoreG, BennettPH, KnowlerWC. Components of the “metabolic syndrome” and incidence of Type 2 diabetes.Diabetes2002; 5: 3120–7.
13.
GrundySM, HansenB, SmithSCJr.,. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management.Circulation2004; 109: 551–6.
14.
DesprésJP. Health consequences of visceral obesity.Ann Med2001; 33: 534–41.
15.
MontalescotG, ColletJP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key.Eur Heart J2005; 8: [ePub ahead of print]
16.
HanleyAJ, WilliamsK, SternMP, HaffnerSM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.Diabet Care2002; 25: 1177–84.
17.
SattarN, GawA, ScherbakovaO. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.Circulation2003; 108: 414–19.
18.
CreagerMA, LuscherTF, CosentinoF, BeckmanJA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.Circulation2003; 108: 1527–32.
19.
McNeillAM, RosomondWD, GirmanCJ. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk In Communities study.Diabet Care2005; 28: 385–90.
20.
LakkaH, LaaksonenD, LakkaT. The metabolic syndrome and total and cardiovascular disease mortality in middle aged men.JAMA2002; 288: 2709–16.
21.
ZellerM, StegPG, RavisyJ. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction.Arch Intem Med2005; 165: 1192–8.
22.
WilsonPW, D'AgostinoRB, PariseH, SullivanL, MeigsJB. Metabolic syndrome as a precursor of cardiovascular disease and Type 2 diabetes mellitus.Circulation2005; 112: 3066–72.
23.
EhrmannDA, BarnesRB, RosenfieldRL, CavaghanMK, ImperialJ. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.Diabet Care1999; 22: 141–6.
24.
SolomonCG, HuFB, DunaifA. Long or highly irregular menstrual cycles as a marker for risk of Type 2 diabetes mellitus.JAMA2001; 286: 2421–6.
25.
HanleyA, WagenknechtL, FestaA. Liver markers and risk of incident metabolic syndrome (MetS) [abstract]. Program and abstracts of the 65th Scientific Sessions of the American Diabetes Association; June 10-14, 2005; San Diego, California.
26.
EckelRH, KraussRM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee.Circulation1998; 97: 2099–100.
27.
ChobanianAV, BakrisGL, BlackHR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.Hypertension2003; 42: 1206–52.
28.
DzauV, BraunwaldE. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement.Am Heart J1991; 121: 1244–63.
29.
BurnierM, BrunnerHR. Angiotensin II receptor antagonists.Lancet2000; 355: 637–45.
30.
WeirMR, DzauVJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management.Am J Hypertens1999; 12: 205S–213S.
31.
CohnJN, TognoniGfor the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.N Engl J Med2001; 345: 1667–75.
32.
PfefferMA, McMurrayJJ, VelazquezEJ. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.N Engl J Med2003; 349: 1893–906.
33.
JuliusS, KjeldsenSE, WeberM. for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.Lancet2004; 363: 2022–31.
34.
CoreaL, CardoniO, FogariR. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.Clin Pharmacol Ther1996; 60: 341–6.
35.
HegnerG, FaustG, FreytagF, MeilenbrockS, SullivanJ, BodinF. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide.Eur J Clin Pharmacol1997; 52: 173–7.
36.
MallionJ-M, BoutelantS, ChabauxP. Valsartan, a new angiotensin II antagonist: blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril.Blood Press Monit1997; 2: 179–84.
37.
MahmudA, FeelyJ. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension.J Hum Hypertens2000; 14: 541–6.
38.
FogariR, ZoppiA, CarrettaR, VeglioF, Salvetti A for the Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study.J Hypertens2002; 20: 1007–14.
39.
CampbellR, SangalliF, PerticucciE. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.Kidney Int2003; 63: 1094–103.
40.
KlingbeilAU, JohnS, SchneiderMP, JacobiJ, HandrockR, SchmiederRE. Effect of AT1 receptor blockade on endothelial function in essential hypertension.Am J Hypertens2003; 16: 123–8.
41.
MallionJ-M, CarrettaR, TrenkwalderP. Valsartan/hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy.Blood Press2003; 12(Suppl 1): 36–43.
42.
CalvoC, HermidaRC, AyalaDE, RuilopeLM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.J Hypertens2004; 22: 837–46.
43.
WaeberB, AschwandenVR, SadeckyL, FerberP. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.J Hypertens2001; 19: 2097–104.
44.
FogariR, MugelliniA, ZoppiA. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension.Eur J Clin Pharmacol2004a; 59: 863–8.
45.
MalaccoE, PiazzaS, ScandianiL, ZoppiA. Valsartan/hydrochlorothiazide versus amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients.Adv Ther2004; 21: 149–61.
46.
MalaccoE, VariN, CapuanoV. for the Val-Syst Investigators. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst Study.Clin Ther2003; 25: 2765–80.
47.
RuilopeLM, MalaccoE, KhderY, KandraA, BonnerG, HeintzD. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.Clin Ther2005; 27: 578–87.
48.
CifkovaR, PeleškaJ, HradecJ. Valsartan and atenolol in patients with severe essential hypertension.J Hum Hypertens1998; 12: 563–7.
49.
FogariR, PretiP, ZoppiA. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women.Am J Hypertens2000;17: 77–81.
50.
European Society of Hypertension-European Society of Cardiology Guidelines Committee.2003European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.J Hypertens 2003; 21: 1011–53.
51.
WhitworthJA. World Health Organization, International Society of Hypertension Writing Group. 2003World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension.J Hypertens 2003;21: 1983–92.
52.
KjeldsenSE, JuliusS, WeberMA, StoltP. Main results from VALUE. In: OparilS, WeberMA, eds. Hypertension: A Companion to Brenner and Rector's The Kidney.2nd ed.Philadelphia, PA: Elsevier Saunders;2005: 376–80.
53.
FogariR, DerosaG, ZoppiA. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.Hypertens Res2005; 28: 209–14.
54.
NomuraS, ShouzuA, OmotoS. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with Type 2 diabetes mellitus.Thromb Res2006; 117: 385–92.
55.
McMurrayJJ, CaliffR, HolmanR. Cardiologists should care about glucose: most people with cardiovascular disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR [abstract].Eur Heart J2004; 25(Suppl): 239.
56.
SharmaAM, JankeJ, GorzelniakK, EngeliS, LuftFC. Angiotensin blockade prevents Type 2 diabetes formation by fat cells.Hypertension2002; 40: 609–11.
57.
CooperME. The role of the renin-angiotensin aldosterone system in diabetes and its vascular complications.Am J Hypertens2004; 17: 16S–20S.
